

# Paradigm Biopharmaceuticals Ltd

19:45 03 Jun 2019

## Paradigm Biopharmaceuticals receives positive results for Ross River clinical trial

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has met its primary endpoint of safety in its pilot phase IIa clinical trial for chronic Ross River virus (RRV) induced arthralgia.

18 patients were dosed, 11 with injectable pentosan polysulfate sodium (iPPS) and 7 with placebos.


Importantly, the primary endpoint of safety was met and encouragingly results demonstrated iPPS reduced RRV disease symptoms compared to the placebo.

For example, at the 3-month follow-up, 72.7% or 8 of the 11 subjects in the iPPS group showed near remission of symptoms based on Rapid-3 disease assessment in contrast to 14.3% or 1 of the 7 in the placebo group.

**Price:** 2.79

**Market Cap:** \$636.32 m

### 1 Year Share Price Graph



October 2019 May 2020 October 2020

### Share Information

**Code:** PAR

**Listing:** ASX

**52 week High Low**  
4.5 1.08

**Sector:** Pharma & Biotech


**Website:** www.paradigmbiopharma.com

### Company Synopsis:

*Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.*

action@proactiveinvestors.com

### RAPID-3 Total (Joint Symptoms)



\* Statistically significant at  $p < 0.05$  from baseline;  
# Not significant from baseline

RAPID-3 scores are correlated with clinical disease activity and enable the quantitative monitoring and documenting of improvement or worsening over time.

A reduction in Rapid 3 signifies improvement in clinical disease activity.

## Successful results to progress commercial discussions

Paradigm's CEO Paul Rennie said: "We are very pleased to see that this small pilot RRV study has yielded very promising safety data and key efficacy outcomes in the reduction of disease symptoms in this debilitating chronic phase of the disease.

"The human data on the effects of iPPS in RRV induced arthralgia together with our preclinical work on CHIK-V will progress our commercial discussions with US Department of Defense."

## **READ: Paradigm Biopharmaceuticals receives more positive real-world patient data**

Recently, Paradigm also received real-world data from 22 more patients with knee osteoarthritis (OA) treated with iPPS.

This increased the total real-world patients treated with iPPS to 205 with a recorded 51.3% reduction in pain.

The 51.3% average reduction in pain score across 205 subjects with knee OA, continues to demonstrate iPPS's superiority over the 15% pain reduction scores reported for opioid treatments for chronic pain in OA of the knee and hip.

Paradigm is aiming to achieve Fast-Track designation and begin a phase 3 trial in the US in CY2019, both these initiatives are expected to attract significant big pharma interest.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).